Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PolyPid Ltd
PYPD | US
4.72
USD0.30
6.79%
PYPD | US
About PolyPid Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
15/04/2026
Close
4.72
Open
4.39
High
4.72
Low
4.39
PolyPid Ltd. a clinical-stage pharmaceutical company develops manufactures and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100 which helps in the prevention of sternal (bone) surgical site infections (SSIs) as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva Israel.
View LessPYPD | US
Risk
50.0
Sharpe
1.79
Luna's Score
51/100
Recommendation
Hold
Luna says (PYPD | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
48.5%1 month
50.0%3 months
45.9%6 months
42.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
14.58
Debt to equity
6.89
Debt to assets
0.56
Ent. to EBITDA
-0.36
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-21.95M
MarketCap
32.11M
MarketCap(USD)
32.11M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-496.62
Short ratio
1.89
Short perc.
0.13
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.67
Range1M
0.69
Range3M
1.11
Volumes: Market Activity
Rel. volume
1.44
Price X volume
422.01K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.36 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 14.58 | 15.55 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 45.85 | - | Lower Risk |
| Debt to Equity | 6.89 | -1.23 | Expensive |
| Debt to Assets | 0.56 | 0.25 | Expensive |
| Market Cap | 32.11M | - | Emerging |
